How to buy Xeris Pharmaceuticals stock (XERS)

Xeris Pharmaceuticals is a biotechnology business based in the US. Xeris Pharmaceuticals shares (XERS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.49 – an increase of 6.4% over the previous week. Xeris Pharmaceuticals employs 377 staff and has a trailing 12-month revenue of around $187.4 million.

Our top picks for where to buy Xeris Pharmaceuticals stock

Buy Xeris Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Xeris Pharmaceuticals stock price (NASDAQ: XERS)

Use our graph to track the performance of XERS stocks over time.

Xeris Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$3.49
52-week range	$1.69 - $3.87
50-day moving average more info button	$3.21
200-day moving average more info button	$2.53
Wall St. target price	$4.77
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.43

Is it a good time to buy Xeris Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Xeris Pharmaceuticals price performance over time

Historical closes compared with the close of $3.49 from 2024-12-20

1 week (2024-12-13)	6.40%
1 month (2024-11-22)	12.94%
3 months (2024-09-20)	19.11%
6 months (2024-06-21)	65.40%

1 year (2023-12-22)	66.99%
2 years (2022-12-22)	176.98%
3 years (2021-12-22)	43.62%
5 years (2019-12-20)	7.56

Xeris Pharmaceuticals financials

Revenue TTM	$187.4 million
Gross profit TTM	$87.6 million
Return on assets TTM	-8.7%
Return on equity TTM	-617.16%
Profit margin	-33.69%
Book value	$-0.19
Market Capitalization more info button	$484.5 million

TTM: trailing 12 months

Xeris Pharmaceuticals share dividends

We're not expecting Xeris Pharmaceuticals to pay a dividend over the next 12 months.

Have Xeris Pharmaceuticals's shares ever split?

Xeris Pharmaceuticals's shares were split on 5 October 2021 .

Xeris Pharmaceuticals share price volatility

Over the last 12 months, Xeris Pharmaceuticals's shares have ranged in value from as little as $1.69 up to $3.87. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xeris Pharmaceuticals's is 1.285. This would suggest that Xeris Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Xeris Pharmaceuticals overview

Xeris Biopharma Holdings, Inc. , a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. .

Frequently asked questions

What percentage of Xeris Pharmaceuticals is owned by insiders or institutions?
Currently 3.921% of Xeris Pharmaceuticals shares are held by insiders and 43.835% by institutions. How many people work for Xeris Pharmaceuticals?
Latest data suggests 377 work at Xeris Pharmaceuticals. When does the fiscal year end for Xeris Pharmaceuticals?
Xeris Pharmaceuticals's fiscal year ends in December. Where is Xeris Pharmaceuticals based?
Xeris Pharmaceuticals's address is: 180 North LaSalle Street, Chicago, IL, United States, 60601 What is Xeris Pharmaceuticals's ISIN number?
Xeris Pharmaceuticals's international securities identification number is: US98422E1038 What is Xeris Pharmaceuticals's CUSIP number?
Xeris Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 98422L107